Essex Bio-Technology Limited (HK:1061)
:1061
1061 Stock Chart & Stats
HK$3.81
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$3.81
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$3.32 - HK$6.12
Previous CloseN/A
Volume76.00K
Average Volume (3M)863.25K
Market Cap
HK$2.05B
Enterprise ValueHK$1.58B
Total Cash (Recent Filing)HK$784.14M
Total Debt (Recent Filing)HK$346.90M
Price to Earnings (P/E)6.7
Beta0.52
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.37%
Share Statistics
EPS (TTM)0.27
Shares Outstanding567,006,000
10 Day Avg. Volume975,600
30 Day Avg. Volume863,250
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)0.89
Price to Sales (P/S)1.18
P/FCF Ratio16.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.84Price Target Upside79.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.65
Revenue Forecast (FY)HK$1.91B
Bulls Say, Bears Say
Bulls Say
High And Stable Gross MarginsSustained ~85–90% gross margins indicate durable product-level profitability and pricing power in biologics. High-margin economics support steady operating profits, enable reinvestment in R&D and manufacturing, and provide buffer against revenue volatility over the medium term.
Conservative, Improving LeverageA declining debt-to-equity ratio and stronger equity base reduce solvency risk and increase financial flexibility. This conservative capital structure supports longer-term investment in capacity or product development and lowers refinancing pressure during economic stress.
Consistently Positive Operating Cash FlowPersistent positive operating cash flow demonstrates that reported profits convert to cash, supporting working capital, routine capex, and shareholder distributions. This cash-generation ability underpins the firm’s capacity to sustain operations and fund strategic initiatives.
Bears Say
Volatile Free Cash FlowLarge swings in free cash flow reduce predictability of internal funding for dividends, M&A, or R&D. A near-50% drop in 2025 implies working-capital pressure or higher investment needs, raising execution risk and potentially forcing external financing at less favorable terms.
Choppy Revenue MomentumIrregular top-line trends hinder long-term planning and make scale-driven margin improvements less reliable. Persistent revenue volatility suggests sensitivity to demand cycles, product mix shifts, or uneven commercial execution, complicating growth forecasting and resource allocation.
Product/revenue ConcentrationRelying mainly on ophthalmology and wound-care biologics concentrates market, regulatory, and reimbursement risk. Limited product diversification makes revenues vulnerable to competitive entrants, clinical setbacks, or changes in hospital procurement, weighing on medium-term resilience.
Essex Bio-Technology News
1061 FAQ
What was Essex Bio-Technology Limited’s price range in the past 12 months?
Essex Bio-Technology Limited lowest stock price was HK$3.32 and its highest was HK$6.12 in the past 12 months.
What is Essex Bio-Technology Limited’s market cap?
Essex Bio-Technology Limited’s market cap is HK$2.05B.
When is Essex Bio-Technology Limited’s upcoming earnings report date?
Essex Bio-Technology Limited’s upcoming earnings report date is Aug 25, 2026 which is in 138 days.
How were Essex Bio-Technology Limited’s earnings last quarter?
Essex Bio-Technology Limited released its earnings results on Mar 23, 2026. The company reported HK$0.273 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.273.
Is Essex Bio-Technology Limited overvalued?
According to Wall Street analysts Essex Bio-Technology Limited’s price is currently Undervalued.
Does Essex Bio-Technology Limited pay dividends?
Essex Bio-Technology Limited pays a Quarterly dividend of HK$0.07 which represents an annual dividend yield of 3.37%. See more information on Essex Bio-Technology Limited dividends here
What is Essex Bio-Technology Limited’s EPS estimate?
Essex Bio-Technology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Essex Bio-Technology Limited have?
Essex Bio-Technology Limited has 567,006,000 shares outstanding.
What happened to Essex Bio-Technology Limited’s price movement after its last earnings report?
Essex Bio-Technology Limited reported an EPS of HK$0.273 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.997%.
Which hedge fund is a major shareholder of Essex Bio-Technology Limited?
Currently, no hedge funds are holding shares in HK:1061
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Essex Bio-Technology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$6.84 (79.53% Upside)
HK$6.84 (79.53% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.30%
12-Months-Change
Fundamentals
Return on Equity
13.57%
Trailing 12-Months
Asset Growth
17.02%
Trailing 12-Months
Company Description
Essex Bio-Technology Limited
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.
1061 Stock 12 Month Forecast
Average Price Target
HK$6.84
▲(79.53% Upside)
Technical Analysis
Hua Medicine
―
Lee's Pharmaceutical Holdings Limited
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Jacobson Pharma Corporation Limited
―
VISEN Pharmaceuticals
―
Options Prices
Currently, No data available
---